Atomic Show #227 – Carmen Bigles, Coqui Radiopharmaceuticals

CarmenBigles-headshot-205x300Coqui Radiopharmaceuticals is a start-up company founded in 2009 with a laser focus on solving a problem affecting the health of tens of thousands of people. The founder, Carmen Bigles, noticed that many of the patients arriving at her clinic had not been properly diagnosed and discovered that the reason for that condition was an insufficient supply of molybdenum-99 to provide technetium-99 for diagnostic nuclear medicine. She recognized that the problem was a solvable one and believed that she had the experience and ability to build a team capable of producing a long term solution.

Ms. Bigles determined that there were proven solutions available, and recognized that the already existing shortage of Mo-99 could not be reliably and promptly solved by starting up a research and development project using novel, unproven ideas.

Her approach to problem solving in this case was to adopt the same solution that had worked for others and to determine the straightest path towards implementing that solution here in the United States.

The path she and her team have chosen is not without risk, but much of the risk in the project comes from regulatory uncertainty and the financial uncertainty that is inherent in a boutique market that has, up until now, been dominated by government-owned, multipurpose facilities that can often afford to sell product at a price that cannot be matched by a private industry.

The perceived regulatory risk can be illustrated with a quote from an article in the November 2014 issue of Nuclear News titled “The Campaign to Resume Domestic Production of Molybdenum.”

Taking on what may be the biggest regulatory challenge is Coqui Pharmaceuticals, a Puerto Rico-based venture that would not only produce reactor-based fission product Mo-99, but would do so in reactors that do not yet exist, and therefore must be permitted and licensed through the NRC.
(Nuclear News, Nov 2014, pg 41)

Despite the doubters, Coqui Radiopharmaceuticals has developed what appears to be a very workable plan, built a strong team, and has engaged consistently with the Nuclear Regulatory Commission.

Just before Ms. Bigles and I spoke, I received a copy of the following press release indicating the achievement of one more milestone on a lengthy, but rewarding journey.


FOR IMMEDIATE RELEASE CONTACT:

Ashley Torres – atorres@krepspr.com
Laura Stace – lstace@krepspr.com
305.663.3543

COQUÍ RADIOPHARMACEUTICALS INKS DEAL WITH INVAP
Nuclear Engineering Firm Chosen as Designer and General Contractor for Florida
Medical Isotope Production Facility

Coral Gables, Fla. (Nov. 20, 2014) — Coquí RadioPharmaceuticals Corp., a medical isotope company working to become the first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to announce it has formally signed a contract with INVAP to design its Medical Isotope Production Facility (MIPF) in Alachua, Fla. Mo-99 is the parent isotope of Technetium-99, which is used in 80 percent of nuclear medicine procedures worldwide. In 2012, Congress passed legislation making it a national priority to produce Mo-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer.

Argentine nuclear engineering firm INVAP has been involved in nuclear development for more than 30 years. During that time it has worked on more than 15 nuclear reactors and related facilities across the world, including several reactors used to produce medical isotopes. Among these is the OPAL reactor in Australia, the ETRR-2 reactor in Egypt, and the NUR reactor in Algeria. Coquí Pharma’s MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia.

“The signing of this contract cements a key step in implementing proven technology to produce Mo-99 for patients requiring lifesaving medical diagnostics,” said Carmen I. Bigles, Coquí Pharma President and CEO. “Today, Coquí Pharma together with INVAP has built a bridge between the U.S. and Argentina, uniting our efforts to ensure the availability and reliability of the most essential radioisotope in nuclear medicine and with the added benefit of making the world a safer place for generations to come by utilizing proven non-proliferation, low-enriched uranium technologies.”

Coquí Pharma is preparing its construction permit application for submission to the U.S. Nuclear Regulatory Commission. Coquí Pharma will utilize existing commercially proven technology with tested designs to license and build a facility that has the capability of reliably supplying a large portion of the U.S. market and international needs.

Due to recent and future projected shortages, the issue of U.S. domestic medical isotope production has been discussed at great length within the industry and U.S. federal government. Coquí Pharma reviewed options available to manufacture Mo-99 and determined that only the INVAP process provides a real, tangible and reliable solution to solve the medical isotope crisis.

# # #

Coquí RadioPharmaceuticals Corp.

Coquí RadioPharmaceuticals Corp. is a medical isotope company, dedicated to the production of Molybdenum-99, which is used in 20 million procedures each year in the U.S. The Puerto Rican company is based in Coral Gables with the mission to bring the foremost medical isotope production facility in the Western Hemisphere to Alachua, Florida, and to create a commercially scalable, reliable supply of medical diagnostic and therapeutic radioisotopes in the U.S. For more information on Coquí RadioPharmaceuticals, visit www.coquipharma.com.

Play

Radiation, Pollution and Radiophobia

Cover - Nuclear Shadowboxing

While researching answers to comments made on the Atomic Insights post titled Healthy doses of radiation, I found a book titled Nuclear Shadowboxing: Legacies and Challenges. It includes a fascinating appendix titled Radiation, Pollution and Radiophobia that should be required reading for people who are interested in understanding more about the health effects of low […]

Read more »

Gold standard nuclear regulator – CNSC

If you want to know something about radiation and have a five minute time window, invest your available time by watching What is Radiation: Understanding Radiation With the Canadian Nuclear Safety Commission. In my opinion, the Canadian Nuclear Safety Commission has lapped the competition. They are in a commanding lead as the true “gold standard” […]

Read more »

Airborne radiation at WIPP

Update: A reader pointed out that the headline is inaccurate. The issue at WIPP is airborne contamination (by radioactive material), not airborne radiation. In order to be gentle with search engines and existing links, the headline will remain as is. End Update. On Friday, February 14 at 11:30 pm, a continuous air monitoring alarm went […]

Read more »

On Plutonium, Nuclear War, and Nuclear Peace

By NNadir I trust — and I hope I am justified in this — that no one wants a nuclear war. I know I don’t. We already have a set of environmental problems that are worse than a limited nuclear war, and may be facing an environmental crisis that might be as dire as a […]

Read more »

Another update on “highly radioactive” water leaks at Fukushima

The media frenzy about the detection of water leaks from the vast tank farm that Tokyo Electric Power Company has been forced to build to store water used to cool the three damaged cores at their Fukushima Daiichi power station continues to sizzle, even in the face of the potential for US attack on Syria. […]

Read more »

UCS is guilty of harming humans by reinforcing fear mongering

Correction: (Posted at 6:43 on 6/16/2013) I made a boneheaded error in the below computation and dropped an important prefix in my units. That error resulted in my final number being off by a factor of 1000; I wrote 0.001 mrem when it should have been 0.001 rem. I apologize for the math error. I […]

Read more »

How much I-131 and Cs-137 was released into atmosphere at Fukushima?

Total mass of main isotopes of concern from Fukushima: I-131 – 43 grams Cs-137 – 4 kilograms The Journal of Nuclear Science and Technology Volume 50, Issue 3, 2013 contains a paper titled Source term estimation of atmospheric release due to the Fukushima Dai-ichi Nuclear Power Plant accident by atmospheric and oceanic dispersion simulations. Using […]

Read more »

Familiarity breeds understanding and acceptance of radiation

After reading Dr. Jerry Cuttler’s paper about the need to restore the basis of radiation regulations to tolerance doses, an Atomic Insights reader provided the link to the above video posted by bionerd23 on YouTube. It is one of several informative videos that she has shared with the world about her explorations to increase both […]

Read more »

Atomic Show #194 – What do you do with the waste?

The first Atomic Show of 2013 is a geeky, chemistry laden discussion aimed at helping to answer the question that many people who fight nuclear energy try to use as their trump card “What do you do with the waste.” It often makes their head spin or makes them put their fingers into their ears […]

Read more »

Radioimmunontherapy (RIT) for follicular lymphoma

Andrew Schorr, the founder and host of Patient Power, interviewed Dr. Anton Hagenbeek of the University Medical Center Utrecht Netherlands about the result of clinical trials of radioimmunotherapy (RIT) to combat follicular lymphoma. The treatment uses a monoclonal antibody that is covalently bound to Y-90, which is a beta emitter. The monoclonal antibody selectively binds […]

Read more »

Dirty Bomb Advice from an Expert – Larry Grimm

With the recent frantic coverage of the GAO’s “sting” of Nuclear Regulatory Commission licensing procedures, the phrase “dirty bomb” is again being thrown about in the popular press. I thought it was time to make the following piece readily available in another location. You might be able to find a similar document somewhere else on […]

Read more »